[go: up one dir, main page]

NO992005L - New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes - Google Patents

New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes

Info

Publication number
NO992005L
NO992005L NO992005A NO992005A NO992005L NO 992005 L NO992005 L NO 992005L NO 992005 A NO992005 A NO 992005A NO 992005 A NO992005 A NO 992005A NO 992005 L NO992005 L NO 992005L
Authority
NO
Norway
Prior art keywords
syndromes
estrogen
prevention
treatment
related diseases
Prior art date
Application number
NO992005A
Other languages
Norwegian (no)
Other versions
NO992005D0 (en
Inventor
Poul Jacobsen
Svend Treppendahl
Paul Stanley Bury
Anders Kanstrup
Lise Brown Christiansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO992005D0 publication Critical patent/NO992005D0/en
Publication of NO992005L publication Critical patent/NO992005L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Foreliggende oppfinnelse ved- rører terapeutisk aktive forbindelser med formel (I) (D en fremgangsmåte for fremstilling av disse forbindelsene, og farmasøytiske preparater som omfatter forbindelsene. De nye forbindelsene kan anvendes ved forhindring eller behandling av østro- genrelaterte sykdommer eller syndromer.BACKGROUND OF THE INVENTION The present invention relates to therapeutically active compounds of formula (I) (D) a process for the preparation of these compounds, and to pharmaceutical compositions comprising the compounds.

NO992005A 1996-10-28 1999-04-27 New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes NO992005L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK119996 1996-10-28
PCT/DK1997/000485 WO1998018778A1 (en) 1996-10-28 1997-10-28 Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes

Publications (2)

Publication Number Publication Date
NO992005D0 NO992005D0 (en) 1999-04-27
NO992005L true NO992005L (en) 1999-06-25

Family

ID=8102089

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992005A NO992005L (en) 1996-10-28 1999-04-27 New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes

Country Status (8)

Country Link
EP (1) EP0934299A1 (en)
JP (1) JP2001502710A (en)
AU (1) AU4772297A (en)
CA (1) CA2270056A1 (en)
IL (1) IL129618A0 (en)
NO (1) NO992005L (en)
WO (1) WO1998018778A1 (en)
ZA (1) ZA979649B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0944613B1 (en) * 1996-12-13 2002-10-09 Chugai Seiyaku Kabushiki Kaisha Benzopyran derivatives
JP2000119187A (en) * 1998-10-15 2000-04-25 Taisho Pharmaceut Co Ltd Composition for preventing or improving depressed mood
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
WO2006032085A1 (en) 2004-09-21 2006-03-30 Novogen Research Pty Ltd Substituted chroman derivatives, medicaments and use in therapy
EP2635273B1 (en) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compositions and methods for the treatment of cancer
AU2016215515B2 (en) 2015-02-02 2020-04-30 Mei Pharma, Inc. Combination therapies
CN120665056A (en) * 2019-12-12 2025-09-19 冰洲石生物科技公司 Novel chroman derivatives having estrogen receptor degrading activity and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) * 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
DE1543749A1 (en) * 1966-02-16 1969-12-11 Merck Ag E Process for the preparation of 3,4-cis-4-aryl-isoflavans
US5280040A (en) * 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
HUP9702244A3 (en) * 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders

Also Published As

Publication number Publication date
EP0934299A1 (en) 1999-08-11
ZA979649B (en) 1998-04-28
AU4772297A (en) 1998-05-22
NO992005D0 (en) 1999-04-27
IL129618A0 (en) 2000-02-29
JP2001502710A (en) 2001-02-27
WO1998018778A1 (en) 1998-05-07
CA2270056A1 (en) 1998-05-07

Similar Documents

Publication Publication Date Title
EG20001A (en) Process for preparing of novel hydrox-amic acid and N-hydroxyurea derivatives and their use
NO20025601L (en) Arylmethylamine derivatives for use as tryptase inhibitors
HK129093A (en) N-tert-butyl-decahydro-2(3-amino-2-hydroxy-4-phenyl-butyl)isoquinoline-3-carboxamide & asparaginyl derivatives thereof
AU2428484A (en) Quinolone carboxylic acids
NO932620L (en) Amindiol protease inhibitors
MD1838F2 (en) 5,6-dichlorbenzimidazole derivatives, process for obtaining thereof, pharmaceutical composition and method of treatment or prevention of herpetic viral infections
ATE233250T1 (en) SACCHARINE DERIVATIVES AS PROTEOLYTIC ENZYMIN HIBITORS
NO971625L (en) Novel peptides with immunomodulatory effects
NO992003D0 (en) New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
NO992005L (en) New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
NO992010L (en) New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
NO992008L (en) New (+) enantiomers of cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
NO992006D0 (en) New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
NO992009L (en) New trans-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
NO992002L (en) New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
NO992007L (en) Novel (-) Enantiomers of cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
NO992004L (en) New cis-3,4-chromane derivatives that can be used in the prevention or treatment of ° estrogen-related diseases or syndromes
FI932654A0 (en) Hydroxamsyraderivat, som hindrar lipoxigenas
EP0386920A3 (en) 2-hydroxy-3-thienyloxypropylamino derivatives
NO20001846L (en) New pharmaceutically active compounds, their preparation and use as ECE inhibitors
RU93030824A (en) Drug for the treatment of psoriasis "Dermapichtol"
WO1998057910A3 (en) Cyclooxygenase-i selective inhibitors and the use thereof as analgesic, antiinflammatory and antiarthritic agents

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application